Skip to main content
PBM logo

Psyence Biomedical Ltd.

PBMNASDAQHealthcareBiotechnology

$3.66Today:- (-)1Y −80.23%

As of Oct 26, 2026 close

Market cap
$2.02M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.92$21.75
Volume (live)
-
Avg. volume (3M)
69.64K

Psyence Biomedical (PBM) Cash Flow Statement

In fiscal 2026 (fiscal year ended Mar 31, 2026), Psyence Biomedical used $8.14M of cash in operating activities and spent $500.23K on capital expenditures. That left free cash flow of −$8.64M.

Psyence Biomedical Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Psyence Biomedical Ltd. (PBM) - Annual data in millions USD
BreakdownFY 2026FY 2025FY 2024FY 2023FY 2022
Period endingMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Operating Activities
Net Income-6.941.01-51.16-0.02-1.86
Depreciation & Amortization0.010.000.000.000.00
Stock Based Compensation0.160.000.320.220.33
Change in Working Capital-1.22-0.39-1.17-0.050.13
Change in Accounts Receivable-0.23-0.100.110.000.10
Change in Accounts Payable0.00-0.360.000.000.00
Change in Other Working Capital-0.370.0743.58-0.050.03
Other Operating Activities-0.37-4.3643.58-0.140.33
Net Cash from Operating Activities-8.14-3.73-2.95-0.52-1.40
Investing Activities
Capital Expenditures-0.50-0.01-0.010.000.00
Acquisitions-4.000.000.000.000.00
Purchases of Investments0.000.000.000.00-255.00
Other Investing Activities-0.01-0.010.000.00254.97
Net Cash from Investing Activities-4.51-0.02-0.010.00-0.03
Financing Activities
Debt Repayment13.967.41-0.150.000.00
Common Stock Issued0.008.150.000.00256.49
Other Financing Activities0.006.410.000.00-1.63
Net Cash from Financing Activities13.969.152.350.00-1.63
Summary
Net Change in Cash1.315.40-0.600.00-3.06
Cash at Beginning of Period6.140.731.330.004.81
Cash at End of Period7.446.140.730.001.76
Free Cash Flow-8.64-3.74-2.95-0.52-1.40

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About Psyence Biomedical Cash Flow

What is Psyence Biomedical's free cash flow?

Psyence Biomedical had negative free cash flow of $8.64M in fiscal 2026 (fiscal year ended Mar 31, 2026), operating cash flow of −$8.14M minus $500.23K of capital expenditures.

How much does Psyence Biomedical spend on capital expenditures?

Psyence Biomedical spent $500.23K on capital expenditures in fiscal 2026, compared with $9.88K a year earlier.

Does Psyence Biomedical pay dividends or buy back shares?

Psyence Biomedical's cash flow statement for fiscal 2026 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition